Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

IBD Serology and Disease Outcomes in African Americans With Crohn's Disease.

Bertha M, Vasantharoopan A, Kumar A, Bruce BB, Prince J, Hofmekler T, Okou D, Chopra P, Wang G, Sauer C, Landers CJ, Hussain SZ, Cross RK, Baldassano RN, Kappelman MD, Katz J, Alexander JS, Kirschner BS, Moulton DE, Osuntokun BO, Patel A, Saeed S, Klapproth JA, Dhere TA, Dubinsky MC, McGovern D, Kugathasan S.

Inflamm Bowel Dis. 2017 Dec 19;24(1):209-216. doi: 10.1093/ibd/izx021.

2.

IFNG rs1861494 polymorphism is associated with IBD disease severity and functional changes in both IFNG methylation and protein secretion.

Gonsky R, Deem RL, Landers CJ, Haritunians T, Yang S, Targan SR.

Inflamm Bowel Dis. 2014 Oct;20(10):1794-801. doi: 10.1097/MIB.0000000000000172.

3.

Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study.

Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP, Weisman MH.

Arthritis Res Ther. 2012 Nov 29;14(6):R261. doi: 10.1186/ar4106.

4.

Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.

Lichtenstein GR, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F, Carroll S, Brown M, Stachelski J, Chuang E, Landers CJ, Stempak JM, Singh S, Silverberg MS.

Inflamm Bowel Dis. 2011 Dec;17(12):2488-96. doi: 10.1002/ibd.21661. Epub 2011 Mar 9.

5.

Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens.

Gonsky R, Deem RL, Landers CJ, Derkowski CA, Berel D, McGovern DP, Targan SR.

Inflamm Bowel Dis. 2011 Jan;17(1):171-8. doi: 10.1002/ibd.21352.

6.

TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets.

Heidemann SC, Chavez V, Landers CJ, Kucharzik T, Prehn JL, Targan SR.

J Clin Immunol. 2010 Jul;30(4):531-8. doi: 10.1007/s10875-010-9382-9. Epub 2010 Mar 27.

7.

Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease.

Ippoliti A, Devlin S, Mei L, Yang H, Papadakis KA, Vasiliauskas EA, McGovern DP, Abreu MT, Melmed G, Shaye O, Enayati P, Chen G, Choi J, Taylor K, Landers CJ, Rotter JI, Targan SR.

Inflamm Bowel Dis. 2010 Aug;16(8):1279-85. doi: 10.1002/ibd.21196.

8.

Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study.

Mundwiler ML, Mei L, Landers CJ, Reveille JD, Targan S, Weisman MH.

Arthritis Res Ther. 2009;11(6):R177. doi: 10.1186/ar2866. Epub 2009 Nov 23.

9.

TLR8-mediated activation of human monocytes inhibits TL1A expression.

Saruta M, Michelsen KS, Thomas LS, Yu QT, Landers CJ, Targan SR.

Eur J Immunol. 2009 Aug;39(8):2195-202. doi: 10.1002/eji.200939216.

10.

IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein.

Michelsen KS, Thomas LS, Taylor KD, Yu QT, Mei L, Landers CJ, Derkowski C, McGovern DP, Rotter JI, Targan SR.

PLoS One. 2009;4(3):e4719. doi: 10.1371/journal.pone.0004719. Epub 2009 Mar 5.

11.

Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation.

Takedatsu H, Taylor KD, Mei L, McGovern DP, Landers CJ, Gonsky R, Cong Y, Vasiliauskas EA, Ippoliti A, Elson CO, Rotter JI, Targan SR.

Gut. 2009 Jan;58(1):60-7. doi: 10.1136/gut.2008.156422. Epub 2008 Oct 2.

12.

Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease.

Shen C, Landers CJ, Derkowski C, Elson CO, Targan SR.

Inflamm Bowel Dis. 2008 Dec;14(12):1641-51. doi: 10.1002/ibd.20645.

13.

TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.

Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, Braun J, Targan SR.

Gastroenterology. 2008 Aug;135(2):552-67. doi: 10.1053/j.gastro.2008.04.037. Epub 2008 May 7.

14.

Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction.

Vandewalle-El Khoury P, Colombel JF, Joossens S, Standaert-Vitse A, Collot M, Halfvarson J, Ayadi A, Landers CJ, Vermeire S, Rutgeerts P, Targan SR, Chamaillard M, Mallet JM, Sendid B, Poulain D.

Am J Gastroenterol. 2008 Apr;103(4):949-57. Epub 2007 Nov 28.

PMID:
18047546
15.

The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells.

Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR.

J Immunol. 2007 Apr 1;178(7):4033-8.

16.

Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations.

Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, Vasiliauskas EA, Fleshner PR, Abreu MT, Taylor K, Landers CJ, Rotter JI, Targan SR.

Inflamm Bowel Dis. 2007 May;13(5):524-30.

PMID:
17260364
17.

NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives.

Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, Abreu MT, Papadakis KA, Vasiliauskas EA, Melmed GY, Fleshner PR, Mei L, Rotter JI, Targan SR.

Gastroenterology. 2007 Feb;132(2):576-86. Epub 2006 Nov 10.

PMID:
17258734
18.

Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease.

Spivak J, Landers CJ, Vasiliauskas EA, Abreu MT, Dubinsky MC, Papadakis KA, Ippoliti A, Targan SR, Fleshner PR.

Inflamm Bowel Dis. 2006 Dec;12(12):1122-30.

PMID:
17119386
19.

Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease.

Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, Vasiliauskas EA, Papadakis KA, Fleshner PR, Rotter JI, Yang H.

Gastroenterology. 2006 Apr;130(4):1078-85.

PMID:
16618402
20.

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression.

Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H; Western Regional Pediatric IBD Research Alliance.

Am J Gastroenterol. 2006 Feb;101(2):360-7.

21.

Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease.

Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR.

J Clin Gastroenterol. 2006 Jan;40(1):55-63.

PMID:
16340635
22.

Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM.

Gastroenterology. 2005 Jun;128(7):2020-8.

PMID:
15940634
23.

Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.

Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J.

Am J Gastroenterol. 2004 Dec;99(12):2376-84.

PMID:
15571586
24.

High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study.

Mow WS, Landers CJ, Steinhart AH, Feagan BG, Croitoru K, Seidman E, Greenberg GR, Targan SR.

Dig Dis Sci. 2004 Aug;49(7-8):1280-6.

PMID:
15387358
25.

Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation.

Prehn JL, Mehdizadeh S, Landers CJ, Luo X, Cha SC, Wei P, Targan SR.

Clin Immunol. 2004 Jul;112(1):66-77.

PMID:
15207783
26.

Bacterial flagellin is a dominant antigen in Crohn disease.

Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM.

J Clin Invest. 2004 May;113(9):1296-306.

27.

Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.

Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR.

Gastroenterology. 2004 Feb;126(2):414-24.

PMID:
14762777
28.

Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens.

Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR.

Gastroenterology. 2002 Sep;123(3):689-99.

PMID:
12198693
29.

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease.

Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H.

Gastroenterology. 2002 Sep;123(3):679-88.

PMID:
12198692
30.

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease.

Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR.

Gastroenterology. 2001 May;120(6):1347-55.

PMID:
11313304
31.
32.

The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease.

Satsangi J, Landers CJ, Welsh KI, Koss K, Targan S, Jewell DP.

Inflamm Bowel Dis. 1998 Feb;4(1):18-26.

PMID:
9552224
33.

Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis.

Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR.

J Pediatr Gastroenterol Nutr. 1998 Apr;26(4):386-92.

PMID:
9552133
34.

A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR.

J Immunol. 1997 Dec 15;159(12):6276-82.

PMID:
9550432
35.

A new syndrome of Crohn's disease and pachydermoperiostosis in a family.

Compton RF, Sandborn WJ, Yang H, Lindor NM, Tremaine WJ, Davis MD, Khalil AA, Tountas NA, Tyan DB, Landers CJ, Taylor KD, Viggiano TR, Matteson EL, Schroeter AL, Plevy SE, Cominelli F, Targan SR, Rotter JI.

Gastroenterology. 1997 Jan;112(1):241-9.

PMID:
8978365
36.

Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.

Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR.

Gastroenterology. 1996 Jun;110(6):1810-9.

PMID:
8964407
37.
38.

Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis.

Zins BJ, Sandborn WJ, Penna CR, Landers CJ, Targan SR, Tremaine WJ, Wiesner RH, Dozois RR.

Am J Gastroenterol. 1995 Dec;90(12):2177-81.

PMID:
8540511
39.

Role of antineutrophil cytoplasmic antibodies in an ethnically distinct population: Korean patients with ulcerative colitis.

Kim WH, Choi PM, Landers CJ, Targan SR.

Am J Gastroenterol. 1995 Nov;90(11):1953-8.

PMID:
7484998
40.

Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients.

Targan SR, Landers CJ, Cobb L, MacDermott RP, Vidrich A.

J Immunol. 1995 Sep 15;155(6):3262-7.

PMID:
7673739
41.

Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis.

Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR.

Am J Gastroenterol. 1995 May;90(5):740-7.

PMID:
7733080
42.

Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis.

Winter HS, Landers CJ, Winkelstein A, Vidrich A, Targan SR.

J Pediatr. 1994 Nov;125(5 Pt 1):707-11.

PMID:
7965422
43.

Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity.

Shanahan F, Duerr RH, Rotter JI, Yang H, Sutherland LR, McElree C, Landers CJ, Targan SR.

Gastroenterology. 1992 Aug;103(2):456-61.

PMID:
1634063
44.

Ulcerative colitis-linked antineutrophil cytoplasmic antibody in the cotton-top tamarin model of colitis.

Targan SR, Landers CJ, King NW, Podolsky DJ, Shanahan F.

Gastroenterology. 1992 May;102(5):1493-8.

PMID:
1568559
45.

Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses.

Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F.

Gastroenterology. 1991 Jun;100(6):1590-6.

PMID:
2019365
46.

Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.

Duerr RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, Shanahan F.

Gastroenterology. 1991 May;100(5 Pt 1):1385-91.

PMID:
2013383

Supplemental Content

Loading ...
Support Center